Pharmaceutical companies have always had access to a steady stream of data to look at what has happened in the past and to try to predict future prescribing trends.
The COVID-19 pandemic has placed enormous stress on both healthcare systems and researchers, and people all across the sector are looking for digital solutions to help ease the pressure.
From AI-driven vaccine candidate selection to the mass roll-out of virtual consultations, digital transformation is accelerating at an unprecedented rate in the face of COVID-19.
Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-u
The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.